Global private equity firm Warburg Pincus has partially exited United States-listed biopharmaceutical company China Biologic Products via a share sale. Warburg sold 2.3 million shares for US$105 apiece, returning a total of US$241.5 million and reducing Warburg’s holding in the company from 43 percent to 34 percent. The transaction was structured though Warburg Pincus Private Equity X.